|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NBPF12 |
Gene summary for NBPF12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NBPF12 | Gene ID | 149013 |
| Gene name | NBPF member 12 | |
| Gene Alias | COAS1 | |
| Cytomap | 1q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A087WUF1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149013 | NBPF12 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.33e-05 | 3.96e-01 | -0.1088 |
| 149013 | NBPF12 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.29e-13 | 5.72e-01 | -0.1954 |
| 149013 | NBPF12 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.29e-02 | 3.72e-01 | -0.1526 |
| 149013 | NBPF12 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.09e-02 | 3.62e-01 | -0.059 |
| 149013 | NBPF12 | HTA11_546_2000001011 | Human | Colorectum | AD | 5.62e-03 | 4.86e-01 | -0.0842 |
| 149013 | NBPF12 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.67e-02 | 5.03e-01 | 0.0131 |
| 149013 | NBPF12 | HTA11_10623_2000001011 | Human | Colorectum | AD | 2.22e-03 | 5.71e-01 | -0.0177 |
| 149013 | NBPF12 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.35e-03 | 9.50e-01 | 0.3487 |
| 149013 | NBPF12 | F007 | Human | Colorectum | FAP | 2.02e-02 | -2.68e-01 | 0.1176 |
| 149013 | NBPF12 | A002-C-010 | Human | Colorectum | FAP | 3.71e-02 | -1.27e-01 | 0.242 |
| 149013 | NBPF12 | A015-C-203 | Human | Colorectum | FAP | 4.96e-13 | 4.16e-02 | -0.1294 |
| 149013 | NBPF12 | A001-C-108 | Human | Colorectum | FAP | 1.07e-06 | -5.29e-02 | -0.0272 |
| 149013 | NBPF12 | A002-C-205 | Human | Colorectum | FAP | 9.39e-04 | -5.95e-02 | -0.1236 |
| 149013 | NBPF12 | A015-C-006 | Human | Colorectum | FAP | 1.73e-03 | -1.87e-01 | -0.0994 |
| 149013 | NBPF12 | A015-C-106 | Human | Colorectum | FAP | 8.32e-05 | -1.47e-01 | -0.0511 |
| 149013 | NBPF12 | A002-C-114 | Human | Colorectum | FAP | 1.92e-04 | -1.26e-01 | -0.1561 |
| 149013 | NBPF12 | A015-C-104 | Human | Colorectum | FAP | 2.28e-11 | -1.52e-01 | -0.1899 |
| 149013 | NBPF12 | A001-C-014 | Human | Colorectum | FAP | 1.46e-02 | -1.00e-01 | 0.0135 |
| 149013 | NBPF12 | A002-C-016 | Human | Colorectum | FAP | 3.55e-06 | -1.27e-01 | 0.0521 |
| 149013 | NBPF12 | A001-C-203 | Human | Colorectum | FAP | 1.70e-02 | -2.79e-02 | -0.0481 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NBPF12 | SNV | Missense_Mutation | novel | c.824N>T | p.Ser275Leu | p.S275L | protein_coding | deleterious(0.03) | possibly_damaging(0.841) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.1084N>A | p.Glu362Lys | p.E362K | protein_coding | tolerated(0.15) | benign(0.237) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.373N>C | p.Glu125Gln | p.E125Q | protein_coding | tolerated(1) | benign(0.022) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.2381N>T | p.Ala794Val | p.A794V | protein_coding | tolerated(0.17) | probably_damaging(0.979) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.373N>C | p.Glu125Gln | p.E125Q | protein_coding | tolerated(1) | benign(0.022) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.168N>C | p.Lys56Asn | p.K56N | protein_coding | tolerated(0.73) | benign(0.009) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR | |
| NBPF12 | SNV | Missense_Mutation | novel | c.2513C>A | p.Thr838Asn | p.T838N | protein_coding | deleterious(0.01) | possibly_damaging(0.646) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| NBPF12 | SNV | Missense_Mutation | novel | c.373N>C | p.Glu125Gln | p.E125Q | protein_coding | tolerated(1) | benign(0.022) | TCGA-A8-A0AB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| NBPF12 | SNV | Missense_Mutation | novel | c.3515G>A | p.Arg1172Lys | p.R1172K | protein_coding | tolerated(0.42) | unknown(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NBPF12 | SNV | Missense_Mutation | novel | c.988A>C | p.Lys330Gln | p.K330Q | protein_coding | tolerated(0.06) | possibly_damaging(0.514) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |